1. Home
  2. ITRG vs TECX Comparison

ITRG vs TECX Comparison

Compare ITRG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$2.47

Market Cap

572.1M

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$30.04

Market Cap

554.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
TECX
Founded
1997
2019
Country
Canada
United States
Employees
N/A
60
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
572.1M
554.1M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ITRG
TECX
Price
$2.47
$30.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$5.13
$75.20
AVG Volume (30 Days)
1.9M
202.4K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$67.34
N/A
Revenue Next Year
$25.89
N/A
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$14.39
52 Week High
$4.87
$35.99

Technical Indicators

Market Signals
Indicator
ITRG
TECX
Relative Strength Index (RSI) 36.20 55.67
Support Level N/A $27.39
Resistance Level $3.29 $31.17
Average True Range (ATR) 0.13 1.94
MACD -0.02 0.16
Stochastic Oscillator 10.24 60.38

Price Performance

Historical Comparison
ITRG
TECX

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: